Ignite Creation Date:
2024-05-06 @ 2:46 PM
Last Modification Date:
2024-10-26 @ 1:37 PM
Study NCT ID:
NCT04425135
Status:
NOT_YET_RECRUITING
Last Update Posted:
2020-06-11
First Post:
2020-06-08
Brief Title:
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy Pemetrixed Carboplatin in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
The First Affiliated Hospital of Xiamen University
Study Overview
Official Title:
Phase II Single-arm Clinical Study of Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy Pemetrixed Carboplatin in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a phase II single-arm clinical studyThe purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy pemetrexed plus carboplatin in patients with advanced non-squamous and non-small cell lung cancer who have failed tyrosine kinase inhibitor therapy and are ALK-positive
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None